Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $81M (up 16.5% year over year) with net income of $13M.
Q3 2026 key financials · XBRL
- Revenue
- $81M
- +16.5% YoY · +2.8% QoQ
- Net income
- $13M
- −52.7% YoY · −23.7% QoQ
- Operating margin
- 21.1%
- EPS (diluted)
- $0.65
- −55.8% YoY · −26.1% QoQ
Source: XBRL data from the RIGEL PHARMACEUTICALS INC (RIGL) Q3 2026 10-Q on SEC EDGAR. USD.
RIGEL PHARMACEUTICALS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $80.9M, up $11.4M YoY from $69.5M
- Product sales $72.3M, up $8.2M YoY, led by TAVALISSE at $46.0M
- Best performer: REZLIDHIA $9.9M, up 20% YoY; worst: GAVRETO $9.8M, down 11%
- Operating cash flow $67.9M through nine months, versus $53.7M YoY; cash and investments $99.3M
- Outlook: product sales expected to increase with VEPPANU launch, offset by rebate, reimbursement and competitive risks
Risk Factors
- New VEPPANU transition risk, triggered by June 11, 2026 license effectiveness and August 13 launch, includes $40.0 million development funding cap
- Most material operational update: Pfizer supply agreement carries $24.8 million estimated minimum-purchase obligation through 2030
- Regulatory risk: CMS’s GLOBE Model final rule starts April 1, 2027, requiring rebates tied to international drug prices
- Competitive risk: Annora’s generic fostamatinib approved June 2026, with sales licensed to begin second quarter 2032
- Financial risk: MidCap revolving facility had $8.0 million outstanding at September 30, 2026, with variable SOFR-based interest
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RIGEL PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.